Biomarkers for Melanoma

• US 20080118462A1
• Filed: 01/09/2006
• Published: 05/22/2008
• Est. Priority Date: 01/07/2005
• Status: Active Grant

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Ryu, Byungwoo, Alani, Rhoda Myra
• Granted Patent: US 8,299,216 B2
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/5743 of skin, e.g. melanoma

Abstract

The present invention relates to methods of determining melanoma status in a subject. The invention also relates to kits for determining melanoma status in a subject. The invention further relates to methods of identifying biomarker for determining melanoma status in a subject.

Claims

1. A biomarker for melanoma status comprising one or more of Markers 1-104 or combinations thereof.

2. The biomarker for melanoma status of claim 1, wherein Markers 78-104 are down-regulated in melanoma subjects.

3. The biomarker for melanoma status of claim 1, comprising Marker 1.

4. The biomarker for melanoma status of claim 1, comprising Markers 1, 6, 24, and 37.

10. The method of claim 1, further comprising:

(d) measuring the at least one biomarker after subject management.

11. The method of claim 1, wherein the melanoma status is selected from one or more of the presence, absence or amount of one or more of biomarkers 1-104.

12. The method of claim 11, further comprising assessing the status of the melanoma.

13. The method of claim 12, wherein the melanoma status is assessed by one or more of visual examination, tissue sample examination, subject'"'"'s symptoms, or evaluation of blood chemistry.

5. A method of qualifying melanoma status in a subject comprising:

(a) measuring at least one biomarker in a sample from the subject, wherein the biomarker is selected from one or more of the biomarkers of Tables 1-3, and

(b) correlating the measurement with melanoma status.

6. The method of claim 5, wherein the melanoma is in one or more of radial growth phase, early vertical growth phase, late vertical growth phase, or metastatic melanoma.

7. The method of claim 5, further comprising:

(c) managing subject treatment based on the status.

8. The method of claim 7, wherein managing subject treatment is selected from ordering further diagnostic tests, administering at least one therapeutic agent, surgery, surgery followed or preceded by administering at least one therapeutic agent, biotherapy, and taking no further action.

9. The method of claim 8, wherein the therapeutic agent is selected from one or more of fotemustine, dacarbazine, interferon, cisplatin, tamoxifen, interleukin-2, ifn alfa, vinblastin, orcarmubris, targeted immunotherapy, or vaccines.

14-22. -22. (canceled)

23. A method for identifying a candidate compound for treating melanoma comprising:

a) contacting one or more of the biomarkers of Tables 1-3 with a test compound; and

b) determining whether the test compound interacts with the biomarker,

wherein a compound that interacts with the biomarker is identified as a candidate compound for treating melanoma.

24. A method of treating melanoma comprising administering to a subject suffering from or at risk of developing melanoma a therapeutically effective amount of a compound capable of modulating the expression or activity of one or more of the biomarkers of Table 1.

25. A method of treating a condition in a subject comprising administering to a subject a therapeutically effective amount of a compound which modulates the expression or activity of one or more of the biomarkers of Tables 1-3.

26-28. -28. (canceled)

29. A method for identifying a melanoma treatment, comprising:

a) contacting a cell with a test compound,

b) measuring at least one biomarker, wherein the biomarker is selected from one or more of the biomarkers of Tables 1-3, and

c) correlating the measurement with a determination of efficacy.

30. The method of claim 29, wherein the cell is one or more of is one or more of a radial-growth phase line, an early vertical-growth phase line, a late vertical growth phase line, or a metastatic melanoma line.

31. A method of determining the melanoma status of a subject, comprising:

(a) obtaining a biomarker profile from a sample taken from the subject; and

(b) comparing the subject'"'"'s biomarker profile to a reference biomarker profile obtained from a reference population, wherein the comparison is capable of classifying the subject as belonging to or not belonging to the reference population;

wherein the subject'"'"'s biomarker profile and the reference biomarker profile comprise one or more markers listed in Table 1.

32-35. -35. (canceled)

36. A method for the identification of a therapeutic target for melanoma comprising:

comparing an expression profile of a melanoma cell with an expression profile of one a reference cell, wherein the comparison is capable of classifying proteins or transcripts in the profile as being associated with invasion.

37-40. -40. (canceled)

41. A purified biomolecule selected from the biomarkers of Tables 1-3.

42. A kit for aiding the diagnosis of melanoma, comprising:

an adsorbent, wherein the adsorbent retains one or more biomarkers selected from one or more of the markers of Table 1, and written instructions for use of the kit for detection of melanoma.

43-45. -45. (canceled)